Results 11 to 20 of about 13,841 (201)
Human Vaccines & Immunotherapeutics, 2020 Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults
John Litt +8 more
doaj +1 more source
PLoS ONE, 2021 ObjectivesComprehensive cost-effectiveness analyses of introducing varicella and/or herpes zoster vaccination in the Swedish national vaccination programme.DesignCost-effectiveness analyses based on epidemiological results from a specifically developed ...
Ellen Wolff +5 more
doaj +1 more source
Effectiveness of herpes zoster vaccination in an older United Kingdom population. [PDF]
, 2018 BACKGROUND: Vaccination against herpes zoster was introduced in the United Kingdom in 2013 for individuals aged 70 years, with a phased catch-up campaign for 71-79 year olds.
Amirthalingam, Gayatri +5 more
core +1 more source
Zoster Meningitis in an Immunocompetent Child after COVID-19 Vaccination, California, USA
Emerging Infectious Diseases, 2022 Varicella zoster virus reactivation after COVID-19 vaccination has been reported in older or immunocompromised adults. We report zoster meningitis from live-attenuated varicella vaccine reactivation in an immunocompetent child after COVID-19 vaccination.
Sarah K. Daouk +3 more
doaj +1 more source
Vaccines, 2023 Background: In Japan, freeze-dried live attenuated varicella-zoster vaccine BIKEN is available for adults aged ≥50 years to prevent herpes zoster (HZ). A prospective cohort study of 1200 healthy adults and 300 patients with underlying illness confirmed ...
Kazuhiro Matsumoto +7 more
doaj +1 more source
Clinical features of varicella-zoster virus infection [PDF]
, 2018 Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia.
Gershon, Anne A., Kennedy, Peter G.E.
core +1 more source
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
Human Vaccines & Immunotherapeutics, 2023 Herpes zoster (HZ) results from waning immunity following childhood infection with varicella zoster virus (VZV) but is preventable by vaccination with recombinant HZ vaccine or live HZ vaccine (two doses or one dose, respectively).
Marta Ulaszewska +3 more
doaj +1 more source
Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms [PDF]
, 2016 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, as are many of the mutations that contribute to the attenuation of the vOka virus for replication in skin. At
Breuer, J +4 more
core +1 more source
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
BMC Medicine, 2018 de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults.
Chester B. Good +2 more
doaj +1 more source
Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. [PDF]
, 2012 In pediatric patients with malignancy and those receiving hematopoietic stem cell transplants, bacterial and fungal infections have been the focus of fever and neutropenia episodes for decades.
Alexander, Sarah +5 more
core +1 more source